Filing summary
Entity mismatch: The request identifies GYRE THERAPEUTICS, INC., but the supplied filing is Catalyst Biosciences, Inc.’s Form 10-K. This summary reflects the supplied filing, not a Gyre Therapeutics filing.
Business context and reporting period
This is Catalyst Biosciences’ annual report for the fiscal year ended December 31, 2018, filed March 7, 2019. The company was a clinical-stage biotechnology company focused principally on engineered coagulation therapies for hemophilia; it had no products approved for sale and no product-sales revenue.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Contract revenue | $6,000 | $1.018 million |
| Research and development expense | $21.474 million | $12.847 million |
| General and administrative expense | $12.354 million | $9.993 million |
| Operating loss | $33.822 million | $21.822 million |
| Net loss | $30.055 million | $21.561 million |
| Net loss per share | $2.68 | $7.45 |
| Cash used in operating activities | $28.553 million | $19.940 million |
R&D expense rose 67%, mainly from DalcA development and manufacturing, anti-C3 research, and higher personnel costs. G&A expense rose 24%. Contract revenue fell sharply as prior ISU Abxis milestone revenue was substantially exhausted. Interest and other income increased to $3.767 million, including $2.229 million of interest income and approximately $1.5 million from an NNR-asset milestone payment.
At year-end, cash and cash equivalents were $31.213 million, short-term investments were $88.914 million, and restricted cash was $50,000. Total assets were $124.920 million, total liabilities $4.975 million, and stockholders’ equity $119.945 million. The company reported no outstanding notes at year-end; redeemable convertible notes matured and were repaid in February 2018. It reported an accumulated deficit of $203.342 million and stated available cash, equivalents, and investments were expected to fund operations for at least 12 months from the filing date.
Financing provided $111.332 million of cash in 2018, principally from a February public offering that yielded $106.762 million net and $9.545 million from warrant exercises, offset in part by $5.082 million of note redemptions. The filing reported no off-balance-sheet arrangements. Fixed contractual obligations totaled $6.305 million, excluding contingent milestones and royalties.
Material changes and operating developments
- MarzAA’s Phase 2 subcutaneous efficacy trial enrolled 11 participants. The company reported clinically significant reductions in annualized bleeding rates among the seven participants who had completed dosing; two participants were still dosing in the filing’s trial update. No anti-drug antibodies or thrombotic events had been detected at that point.
- DalcA’s Phase 1/2 trial showed increased Factor IX activity with daily subcutaneous dosing. Two participants in a later cohort developed neutralizing antibodies; the company’s investigation concluded the candidate’s immunogenicity risk was similar to commercial wild-type FIX products, and it planned to continue development.
- The December 2018 amended ISU Abxis agreement gave Catalyst worldwide development, manufacturing, and commercialization rights for DalcA except South Korea, where ISU Abxis retained commercialization rights. Catalyst may owe up to $19.5 million in milestones and low single-digit royalties on eligible sales outside South Korea.
- The company amended its Mosaic research collaboration for anti-C3 products. Collaboration expense was $1.3 million in 2018 versus $30,000 in 2017; the CEO and a director also served on Mosaic’s board, and the filing says disinterested directors and the audit committee reviewed and approved the transaction.
Outlook, risks, and unusual items
- Management expected 2019 R&D expense to increase materially, driven mainly by MarzAA and DalcA clinical trials and manufacturing. Plans included completing the MarzAA Phase 2 portion in the second half of 2019, initiating a Phase 1 subcutaneous pharmacokinetic/pharmacodynamic study in the second quarter of 2019, and starting a six-person DalcA Phase 2b study in the first quarter of 2019.
- The company planned a global MarzAA Phase 3 study in 2020, subject to development progress. These are plans and expectations, not assured outcomes.
- Major risks include clinical efficacy and safety uncertainty, DalcA neutralizing antibodies, future funding needs and potential dilution, dependence on outside manufacturers and clinical-service providers, regulatory approval, competition, reimbursement, and intellectual-property challenges. The filing describes a European patent that may cover MarzAA and an appeal the company had filed.
- The company paid Pfizer a $1 million milestone in 2018 and may owe Pfizer up to $17.5 million in further milestone payments, plus single-digit royalties if covered products are commercialized. It also had remaining AGC manufacturing obligations and contingent ISU Abxis milestones.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective at year-end.
Investor verification priorities
- Confirm the intended issuer: the supplied filing is for Catalyst Biosciences, not GYRE THERAPEUTICS, INC.
- Check subsequent filings for actual cash runway, financing, share dilution, and changes to management’s 12-month liquidity outlook.
- Verify updated MarzAA and DalcA trial enrollment, efficacy, safety, antibody findings, and timing against later clinical disclosures.
- Review the full ISU Abxis, Pfizer, AGC, and Mosaic agreements for milestone conditions, royalties, remaining payments, and related-party terms.
- Assess the status of the MarzAA-related patent appeal and any other intellectual-property disputes or licensing developments.